Health Care·Biotechnology·$11.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.56 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.56 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about their clinical developments. They reiterated their focus on advancing their research pipeline but did not provide specific guidance for the future.
Management highlighted ongoing progress in clinical trials.
They emphasized a commitment to advancing their pipeline.
No specific updates on future guidance were provided.
Madrigal Pharmaceuticals' Q3 2018 earnings report shows a loss per share of $0.56, but the stock reacted positively, rising 4.18%. The increase in stock price may reflect investor confidence in the company's ongoing clinical trials and future potential. However, the lack of revenue data and guidance leaves some uncertainty about the company's immediate financial outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
OCCIDENTAL PETE CORP
Nov 5, 2018